Kala Bio, INC

Kala Bio, Inc. is implementing a 1-for-50 reverse stock split to adjust its common stock, effective May 8, 2026, with trading on a split-adjusted basis beginning May 11, 2026.

KALA BIO, Inc. announced a strategic shift to become an AI infrastructure partner for the biotechnology industry, securing an exclusive license for Younet AI's Researgency platform.

KALA BIO, Inc. announced the immediate resignation of David Lazar as CEO and CFO, appointing current director Avi Minkowitz to both roles.

KALA BIO, Inc. completed the second closing of its private placement, raising $4.2 million, alongside significant board changes and an increase in authorized common stock.

KALA BIO, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

KALA BIO, Inc. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $15 million of common stock.

KALA BIO reports Q1 2026 financial results while transitioning from a clinical-stage biopharmaceutical company to an AI platform-as-a-service provider.

KALA BIO, Inc. announced the failure of its key clinical trial, leading to a default on its primary loan, asset foreclosure by Oxford Finance, significant workforce reductions, and substantial doubt about its ability to continue as a going concern.

KALA BIO, Inc. reported significant losses and negative cash flows for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite progress in its KPI-012 clinical trial.

KALA BIO, Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for KPI-012 and expressing substantial doubt about its ability to continue as a going concern.

Kala Bio, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing clinical development of KPI-012 and its financial position.

Kala Bio, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical development of KPI-012 and recent financing activities.

Kala Bio, Inc. announces a strategic pivot towards developing an AI infrastructure platform for the biotech industry, following the discontinuation of its KPI-012 biologics program.

KALA BIO, Inc. files its 10-K, summarizing its financial results for 2024 and providing updates on the clinical development of KPI-012 for persistent corneal epithelial defects (PCED).

Kala Bio, Inc.'s 10-K filing outlines its capital structure, ongoing clinical trials for KPI-012, and regulatory considerations.

KALA BIO, Inc. CEO David E. Lazar's convertible loan of up to $375,000 was fully repaid in cash by the issuer on December 18, 2025, foregoing conversion into common stock.

KALA BIO's CEO, David E. Lazar, acquired 900,000 shares of Series AA Convertible Preferred Stock for $1.8 million, with plans for a further $4.2 million investment.

KALA BIO, Inc. Director Mark T. Iwicki reported the sale of 154,894 shares of common stock at a weighted average price of $0.81 per share.

KALA BIO's Chief Financial Officer, Mary Reumuth, reported the sale of 33,197 common shares under a pre-arranged trading plan.

KALA BIO Director Todd Bazemore sold 47,768 shares of common stock at a weighted average price of $0.83 per share, reducing his direct beneficial ownership.

KALA BIO's Head of R&D and Chief Medical Officer, Romulus K. Brazzell, has reported a planned sale of 46,748 shares of common stock at a weighted average price of $0.83 per share on October 22, 2025, under a Rule 10b5-1 trading plan.

Kala Bio, Inc. filed a supplement to its 2025 Annual Meeting proxy statement, updating the biography of Class II Director Nominee David Lazar to reflect his recent and current executive and board roles across multiple public companies.

Kala Bio, Inc. filed a supplement to its 2025 Proxy Statement, detailing new related party share issuances and an updated count of outstanding common stock.

KALA BIO, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, executive compensation, auditor ratification, preferred stock conversion, increased authorized shares, and a reverse stock split.

KALA BIO is reminding stockholders to vote on proposals for the upcoming annual meeting on June 11, 2024.

KALA BIO, INC. is holding its annual meeting on June 11, 2024, seeking stockholder votes on director elections, executive compensation, auditor ratification, stock issuance, and amendments to preferred stock designations.

KALA BIO is asking stockholders to vote on the election of directors, executive compensation, auditor ratification, and amendments to preferred stock designations at its annual meeting on June 11, 2024.

David E. Lazar amends Schedule 13D, reporting beneficial ownership of 719,404 shares, representing 3.9% of Kala Bio, Inc.'s outstanding common stock.

David E. Lazar has acquired a 5.18% beneficial ownership in KALA BIO, Inc. through convertible preferred stock, was appointed CEO and board member, but subsequently resigned as CEO while remaining on the board.

SR One Capital Management entities have reduced their beneficial ownership in KALA BIO, Inc. to 4.6% after converting preferred stock and selling common shares.

Baker Bros. Advisors LP and affiliates have reduced their beneficial ownership in KALA BIO, Inc. to 9.99%, resulting in the loss of their right to nominate directors to the company's Board.

SR One Capital Management and its affiliates reported the sale of 598,940 shares of KALA BIO, Inc. common stock, reducing their beneficial ownership to 5.5%.

LifeSci Capital LLC and its managers, Andrew McDonald and Michael Rice, have reported a beneficial ownership of 7.9% in KALA BIO, Inc. common stock.

Oxford Finance LLC has reported a 16.5% beneficial ownership stake in KALA BIO, Inc., holding 1,620,000 shares of common stock.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 0.0% beneficial ownership in KALA BIO, Inc. as of September 30, 2025.

Perceptive Advisors and related entities report 0% beneficial ownership in KALA BIO, Inc. common stock.

Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G, reporting zero beneficial ownership in KALA BIO, Inc.'s common stock as of September 30, 2025.

Baker Bros. Advisors and affiliates have reclassified their KALA BIO, Inc. stake to a passive 9.99% ownership, relinquishing board nomination rights.